Novo Nordisk A/S Common Stock (NVO)

UNH, SBUX, NVO, UPS, META were among the stocks seen trending on Tuesday, July 29, 2025.

It seemed the market overreacted to discouraging news from one of the company's rivals.

Novo Nordisk A/S (NYSE:NVO) has evolved over the past century from a humble insulin manufacturer in Denmark into one of the world’s most valuable pharmaceutical companies. With a commanding presence in diabetes care and a rapidly expanding footprint in obesity, rare disease, and cardiovascular treatments, the company's

In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at the top echelons of the Danish drugmaker sent shockwaves through the investor community, wiping billions off its market capitalization and

The Ozempic maker's stock is dropping fast -- here's why.

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after treatment.

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.

The company now expects full-year sales growth of 8% to 14% at a constant exchange rate, down from its previous estimate of 13% to 21%.

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Novo Nordisk lowered its full-year guidance and named a new CEO. The pharma giant's shares plunged in early trades.

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

These big pharma stocks arguably aren't receiving the respect they deserve.

Wall Street might be underestimating these companies' potential.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market.

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims.

The Caviar Cruise stock screener identifies top long-term investments like Novo Nordisk (NVO), with strong revenue growth, high ROIC, solid cash flow, and pricing power—ideal for quality investors.